Last updated Manufacturer: Merck Sharp & Dohme Corp Generic name: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Gardasil Safety With almost 30,000 adverse events reported to the US Vaccine Adverse Event Reporting System in only 9 years, HPV vaccines are the most controversial vaccine type of recent years. Safety concerns have led to the vaccine being withdrawn in Spain and Japan. Merck says in its information that they conducted 7 clinical trials. In 5 out of 7, the placebo group received Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS), the adjuvant used in Gardasil. One trial used a saline placebo and one was uncontrolled. In presenting the results, Merck compares adverse reaction from Gardasil to the placebo groups but does not always make clear whether that placebo group received saline solution or AAHS. Only for local “injection-site” reactions was this shown and both Gardasil and the AAHS group often had many times the adverse reactions than saline placebo. But for systemic adverse events, i.e. the important ones, they do not make clear whether they are comparing Gardasil to saline placebo or AAHS placebo. In examining systemic autoimmune disorders, the same percentage in both the vaccine and the placebo group had such adverse reaction, In this particular example, however, careful reading revels that among the placebo recipients, only 4.5% received a saline placebo and the rest received Amorphous Aluminum Hydroxyphosphate Sulfate. The results are consequently meaningless as they only show Gardasil being not much worse than its adjuvant alone. Adverse events were recorded up to 14 days following injection of each dose. Merck says that “Of the entire study population (29,323 individuals), 0.04% of the reported serious systemic adverse reactions were judged to be vaccine related by the study investigator [i.e. themselves].” [1] The vaccine was approved by the European…

This content is for VIP members only.
Log In Register